Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of GALECTO INC
Analyst Grade Summary
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
0
3
2
0
0
No Price
01.05.2026 19:59
Current Prices from GALECTO INC
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
NASDAQ
GLTO
USD
01.05.2026 19:59
25,44 USD
-0,32 USD
-1,24 %
Share Float & Liquidity
Free Float92,37 %
Shares Float1,48 M
Shares Outstanding1,6 M
Company Profile for GALECTO INC Share
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
